Format

Send to

Choose Destination
BMC Cancer. 2016 Sep 1;16:707. doi: 10.1186/s12885-016-2740-0.

Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.

Author information

1
Department of Surgery, Trinity Translational Medicine Insitiute, Trinity Health Sciences Centre, Trinity College Dublin/St. James' Hospital, Dublin 8, Ireland.
2
Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Health Centre, Trinity College Dublin/St. James' Hospital, Dublin 8, Ireland.
3
Cancer and Aging Research Program, Queensland University of Technology, Brisbane, Queensland, Australia.
4
Department of Surgery, Trinity Translational Medicine Insitiute, Trinity Health Sciences Centre, Trinity College Dublin/St. James' Hospital, Dublin 8, Ireland. pidgeong@tcd.ie.

Abstract

BACKGROUND:

Baicalein is a widely used Chinese herbal medicine derived from Scutellaria baicalenesis, which has been traditionally used as anti-inflammatory and anti-cancer therapy. In this study we examined the anti-tumour pathways activated following baicalein treatment in non-small cell lung cancer (NSCLC), both in-vitro and in-vivo.

METHODS:

The effect of baicalein treatment on H-460 cells in-vitro was assessed using both BrdU assay (cell proliferation) and High Content Screening (multi-parameter apoptosis assay). A xenograft nude mouse model was subsequently established using these cells and the effect of baicalein on tumour growth and survival assessed in-vivo. Tumours were harvested from these mice and histological tissue analysis carried out. VEGF, 12-lipoxygenase and microvessel density (CD-31) were assessed by immunohistochemistry (IHC), while H and E staining was carried out to assess mitotic index. Gene expression profiling was carried out on corresponding RNA samples using Human Cancer Pathway Finder Arrays and qRT-PCR, with further gene expression analysis carried out using qRT-PCR.

RESULTS:

Baicalein significantly decreased lung cancer proliferation in H-460 cells in a dose dependent manner. At the functional level, a dose-dependent induction in apoptosis associated with decreased cellular f-actin content, an increase in nuclear condensation and an increase in mitochondrial mass potential was observed. Orthotopic treatment of experimental H-460 tumours in athymic nude mice with baicalein significantly (p < 0.05) reduced tumour growth and prolonged survival. Histological analysis of resulting tumour xenografts demonstrated reduced expression of both 12-lipoxygenase and VEGF proteins in baicalein-treated tumours, relative to untreated. A significant (p < 0.01) reduction in both mitotic index and micro-vessel density was observed following baicalein treatment. Gene expression profiling revealed a reduction (p < 0.01) in both VEGF and FGFR-2 following baicalein treatment, with a corresponding increase (p < 0.001) in RB-1.

CONCLUSION:

This study is the first to demonstrate efficacy of baicalein both in-vitro and in-vivo in NSCLC. These effects may be mediated in part through a reduction in both cell cycle progression and angiogenesis. At the molecular level, alterations in expression of VEGF, FGFR-2, and RB-1 have been implicated, suggesting a molecular mechanism underlying this in-vivo effect.

KEYWORDS:

Angiogenesis; Apoptosis; Baicalein; NSCLC; Survival; in-vivo

PMID:
27586635
PMCID:
PMC5009689
DOI:
10.1186/s12885-016-2740-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center